Swiss Biotech Report 2021
- 21.04.22
- Switzerland is one of the leading global biotech hubs in the world. The
latest edition of the Swiss Biotech Report, published by the Swiss Biotech
Association in cooperation with EY and eight other partner organizations
shows the prominent position with record levels of investment in 2020:
the R&D investments increased by 10 % to CHF 2,2 billion. The 2021
report highlights Switzerland’s role in responding to the pandemic through
basic research (e.g. cloning and 3D structure of the virus), vaccine manufacture
and component supply (e.g. Lonza, Bachem, Janssen Cilag), diagnostics (e.g.
Roche, Quotient, Ender, Mosaiq, Biolytix) and therapeutics (Humabs Biomed/Vir
Biotechnologies, Molecular Partners/Novartis).
The Swiss Biotech Report 2021 is available at SWISS BIOTECH.
The Swiss Biotech Report 2021 (pdf)
